Dr. Costa on the Patients Included in the OlympiA Trial in HER2- Breast Cancer

Video

In Partnership With:

Ricardo Costa, MD, MSc, discusses the patient population included in the phase 3 OlympiA trial in breast cancer.

Ricardo Costa, MD, MSc, medical oncologist, Department of Breast Oncology, Clinical Investigator Track, Moffitt Cancer Center, discusses the patient population included in the phase 3 OlympiA trial (NCT02032823) in breast cancer.

Findings from the randomized OlympiA trial demonstrated a statistically meaningful improvement in disease-free survival with adjuvant olaparib (Lynparza) vs placebo in patients with BRCA1/2-mutant, HER2-negative, early-stage breast cancer. The large, multinational trial enrolled over 800 patients with germline pathogenic or likely pathogenic BRCA1/2 mutations. Patients were randomized 1:1 to treatment with one year of adjuvant olaparib or placebo, Costa says. 

Inclusion criteria for OlympiA stated that patients needed have a diagnosis of HER2–negative disease, Costa adds. Moreover, the majority of patients enrolled on the study had triple-negative breast cancer, Costa concludes.

Related Videos
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD